QNCX Quince Therapeutics Inc

Price (delayed)

$0.7

Market cap

$30.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$22.44M

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence ...

Highlights
The EPS rose by 37% year-on-year and by 10% since the previous quarter
The net income rose by 28% YoY and by 3.5% QoQ
The quick ratio has plunged by 76% YoY and by 12% from the previous quarter
The equity has decreased by 18% YoY and by 13% QoQ

Key stats

What are the main financial stats of QNCX
Market
Shares outstanding
43.22M
Market cap
$30.25M
Enterprise value
$22.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.2M
EBITDA
-$29.85M
Free cash flow
-$23.14M
Per share
EPS
-$0.76
Free cash flow per share
-$0.54
Book value per share
$1.73
Revenue per share
$0
TBVPS
$1.86
Balance sheet
Total assets
$159.29M
Total liabilities
$85.12M
Debt
$14M
Equity
$74.18M
Working capital
$60.6M
Liquidity
Debt to equity
0.19
Current ratio
7.16
Quick ratio
6.89
Net debt/EBITDA
0.26
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-24.2%
Return on equity
-36.8%
Return on invested capital
-46.8%
Return on capital employed
-20.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QNCX stock price

How has the Quince Therapeutics stock price performed over time
Intraday
7.69%
1 week
-1.41%
1 month
-18.6%
1 year
-50%
YTD
-33.33%
QTD
-33.96%

Financial performance

How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.69M
Net income
-$30.28M
Gross margin
N/A
Net margin
N/A
QNCX's operating income is up by 34% year-on-year and by 13% since the previous quarter
The net income rose by 28% YoY and by 3.5% QoQ

Growth

What is Quince Therapeutics's growth rate over time

Valuation

What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 37% year-on-year and by 10% since the previous quarter
QNCX's P/B is 92% below its 5-year quarterly average of 5.0 and 33% below its last 4 quarters average of 0.6
The equity has decreased by 18% YoY and by 13% QoQ

Efficiency

How efficient is Quince Therapeutics business performance
The ROIC has increased by 40% year-on-year and by 11% since the previous quarter
Quince Therapeutics's ROA has increased by 39% YoY and by 16% from the previous quarter
The ROE has increased by 12% YoY

Dividends

What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QNCX.

Financial health

How did Quince Therapeutics financials performed over time
QNCX's total assets is 87% greater than its total liabilities
The quick ratio has plunged by 76% YoY and by 12% from the previous quarter
The current ratio has plunged by 76% YoY and by 11% from the previous quarter
The debt is 81% lower than the equity
QNCX's debt to equity is up by 19% since the previous quarter
The equity has decreased by 18% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.